KALLIKREINS AND KININS IN HYPERTENSION

Information

  • Research Project
  • 3335404
  • ApplicationId
    3335404
  • Core Project Number
    R01HL017705
  • Full Project Number
    5R01HL017705-15
  • Serial Number
    17705
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/1/1978 - 47 years ago
  • Project End Date
    1/31/1992 - 33 years ago
  • Program Officer Name
  • Budget Start Date
    2/1/1989 - 36 years ago
  • Budget End Date
    1/31/1990 - 35 years ago
  • Fiscal Year
    1989
  • Support Year
    15
  • Suffix
  • Award Notice Date
    1/1/2999 - 974 years from now

KALLIKREINS AND KININS IN HYPERTENSION

The objective is to determine whether tissue kallikreins contribute to the pathology of genetic forms of hypertension in animal models, and ultimately, in man. Important advances in knowledge about tissue kallikreins, their gene families, synthesis and regulation, localization and functional responsibilities, and abnormality in hypertensive states were made over the last five years. The role of tissue kallikreins and their kinin products in renal and intestinal ion and water transport is being revealed, especially in regard to calcium-dependent electrogenic chloride secretion and ADH-stimulated water flow. Components of tissue kallikrein-kinin system(s) are present in the brain and show responses to stimuli important to cardiovascular homeostasis. The demonstration of kallikrein-like enzyme(s) in the vascular wall presents a new opportunity for study of a system suggested to have a role in regulation of vascular resistance. We will use new tools to explore regulation, levels of activity, and roles of tissue kallikreins and their products in the above-mentioned sites in spontaneously hypertensive or Dahl rats. They include: kallikrein mRNA, synthesis rate, zymogen, and active enzyme measurements; the ability to develop and/or maintain primary cell cultures which either contain or are responsive to kallikrein system components; the ability to measure other system components (e.g., kinins, kininogen, a new tissue kallikrein binding protein) or biophysical and biochemical responses to such components (e.g., ion fluxes, channel behavior via patch clamping, eicosanoid synthesis or phosphoinositide turnover); monoclonal antibodies to tissue kallikreins which inhibit or stimulate the enzyme; and kinin receptor blockers. Our specific aims are: 1) to compare tissue kallikrein systems in genetic hypertensive models and their controls; 2) to further explain the roles of tissue kallikreins and kinins in membrane transporting events which relate to cardiovascular homeostasis; 3) to determine whether tissue kallikrein systems contribute causally to genetic forms of hypertensive disease; 4) to pursue these objectives in concert with collaborators who provide different perspectives through work on kallikrein gene expression and enzyme responsibilities, and the role of kallikreins in diabetic renal function.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
    SCHOOL OF MEDICINE &DENTISTRY
  • Funding ICs
  • Funding Mechanism
  • Study Section
    CVB
  • Study Section Name
    Cardiovascular and Pulmonary Research B Study Section
  • Organization Name
    MEDICAL UNIVERSITY OF SOUTH CAROLINA
  • Organization Department
  • Organization DUNS
    183710748
  • Organization City
    CHARLESTON
  • Organization State
    SC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    29425
  • Organization District
    UNITED STATES